| abstract |
The present invention provides a prior release compartment comprising aspirin, or a pharmaceutically acceptable salt thereof as a pharmacologically active ingredient, and a delayed release compartment comprising clopidogrel, an isomer thereof, or a pharmaceutically acceptable salt thereof, as a pharmacologically active ingredient. It provides a combination formulation comprising a. The combination formulation of the present invention exhibits much better anti-platelet aggregation effect than that of each monotherapy or co-treatment treatment, and can improve patient compliance with the aspirin as a daily dosage form. May reduce side effects. In addition, the combination preparation of the present invention exhibits excellent platelet aggregation inhibitory effect in spite of a dose reduction of aspirin, converts clopidogrel resistance to susceptibility, prevents significant side effects due to clopidogrel resistance, and is stable under general storage conditions for long-term storage. This has a possible advantage.n n n n Prior release, delayed release, time difference, clopidogrel, aspirin, combination |